TY - JOUR
T1 - Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)
AU - Gerratana, Lorenzo
AU - Zhang, Qiang
AU - Shah, Ami Naimish
AU - Davis, Andrew Adam
AU - Zhang, Youbin
AU - Wehbe, Firas
AU - Qiang, Wenan
AU - Flaum, Lisa
AU - Finkelman, Brian Steven
AU - Gradishar, William John
AU - Platanias, Leonidas C.
AU - Behdad, Amir
AU - Cristofanilli, Massimo
N1 - Funding Information:
This study was evaluated and approved by the Northwestern University IRB under the single Institution Investigator Initiated Prospective Trial (IIT) NU16B06.
Funding Information:
This work was supported by Lynn Sage Cancer Research Foundation and Predicine. The data interpretation and reporting included in the manuscript were performed independently from Predicine.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.
AB - Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.
KW - Circulating tumor DNA
KW - Clinical utility
KW - Next generation sequencing
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85076828158&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.102856
DO - 10.1016/j.critrevonc.2019.102856
M3 - Review article
C2 - 31884205
AN - SCOPUS:85076828158
SN - 1040-8428
VL - 145
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 102856
ER -